{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:24:49Z","timestamp":1778869489591,"version":"3.51.4"},"reference-count":86,"publisher":"Informa UK Limited","issue":"16","funder":[{"name":"AbbVie"},{"name":"Bristol Myers-Squibb"},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Janssen"},{"name":"Eli Lilly"},{"name":"Novartis"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.2217\/imt-2019-0116","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T11:32:26Z","timestamp":1570102346000},"page":"1357-1370","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":6,"title":["Risankizumab in Moderate-to-Severe Plaque Psoriasis"],"prefix":"10.1080","volume":"11","author":[{"given":"Linda","family":"Serrano","sequence":"first","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Maloney","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth B","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, 8701 Watertown Plank Rd, Milwaukee, WI 53226, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8634-3"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.143.12.1559"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.09.042"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20061475"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2018.80718"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042915-103905"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.07.064"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6621"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.12788\/j.sder.2018.047"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.043"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1292137"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14868"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14433"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806382"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1088"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.12.005"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60725-4"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60726-6"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.10941.x"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0198-x"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2005.06688.x"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67566-6"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.09.010"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.04.013"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.037"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1556465"},{"key":"e_1_3_2_38_1","unstructured":"A study to evaluate the efficacy and safety of mirikizumab (LY3074828) in participants with moderate-to-severe plaque psoriasis. Eli Lilly and Company.https:\/\/ClinicalTrials.gov\/show\/NCT03482011"},{"key":"e_1_3_2_39_1","unstructured":"A study of mirikizumab in participants with plaque psoriasis. Eli Lilly and Company.https:\/\/ClinicalTrials.gov\/show\/NCT03718884"},{"key":"e_1_3_2_40_1","unstructured":"A study to assess if mirikizumab is effective and safe compared to secukinumab and placebo in moderate to severe plaque psoriasis (OASIS-2). Eli Lilly and Companyhttps:\/\/ClinicalTrials.gov\/show\/NCT03535194"},{"key":"e_1_3_2_41_1","unstructured":"A study of mirikizumab (LY3074828) in participants with moderate to severe plaque psoriasis. Eli Lilly and Company.https:\/\/ClinicalTrials.gov\/show\/NCT02899988"},{"key":"e_1_3_2_42_1","unstructured":"A long-term study to evaluate safety and maintenance of treatment effect of LY3074828 in participants with moderate-to-severe plaque psoriasis (OASIS-3). Eli Lilly and Company.https:\/\/ClinicalTrials.gov\/show\/NCT03556202"},{"key":"e_1_3_2_43_1","unstructured":"A safety study of mirikizumab (LY3074828). Eli Lilly and Companyhttps:\/\/ClinicalTrials.gov\/show\/NCT01947933"},{"key":"e_1_3_2_44_1","volume-title":"American Academy of Dermatology Annual Meeting","author":"Armstrong Aw PL","year":"2019","unstructured":"Armstrong Aw PL , JoshiA , SkupMet al. The comparative efficacy for novel treatments of moderate to severe plaque psoriasis. Presented at: American Academy of Dermatology Annual Meeting. Washington DC, USA, 1\u20135 March 2019."},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.018"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00759-z"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01136-7"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030451"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1032491"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041257"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S165943"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1398.006"},{"key":"e_1_3_2_55_1","unstructured":"BI 655066 (risankizumab) proof of concept dose finding study in ankylosing spondylitis (AS). Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT02047110"},{"key":"e_1_3_2_56_1","unstructured":"Efficacy and safety of BI 655066\/ABBV-066 (risankizumab) in patients with severe persistent asthma. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT02443298"},{"key":"e_1_3_2_57_1","unstructured":"Efficacy safety and pharmacokinetics of BI 655066\/ABBV-066 (risankizumab) in patients with active moderate-to-severe Crohn\u2019s disease. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT02031276"},{"key":"e_1_3_2_58_1","unstructured":"A global study comparing risankizumab to placebo in adult participants with moderate to severe hidradenitis suppurativa. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT03926169"},{"key":"e_1_3_2_59_1","unstructured":"A multicenter randomized double-blind placebo controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis who have failed prior biologic therapy. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT03398148"},{"key":"e_1_3_2_60_1","unstructured":"A study to evaluate risankizumab in adult and adolescent subjects with moderate to severe atopic dermatitis. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT03706040"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0730-x"},{"key":"e_1_3_2_62_1","unstructured":"Single rising dose study of BI 655066 in patients with moderate and severe psoriasis. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT01577550"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.15513541-8"},{"key":"e_1_3_2_64_1","unstructured":"BI 655066 ABBV-066 (risankizumab) in moderate to severe plaque psoriasis with randomized withdrawal and re-treatment. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT02672852"},{"key":"e_1_3_2_65_1","volume-title":"American Academy of Deramtology Annual Meeting","author":"Langley Rg BA","unstructured":"Langley Rg BA , GooderhamM , PappKet al. Efficacy and safety of continuous Q12W risankizumab versus treatment withdrawal: results from the Phase III IMMhance trial. Presented at: American Academy of Deramtology Annual Meeting. Washington DC, USA, 1\u20135 March 2019."},{"key":"e_1_3_2_66_1","unstructured":"BI 655066\/ABBV-066 (risankizumab) compared to active comparator (adalimumab) in patients with moderate to severe chronic plaque psoriasis. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT02694523"},{"issue":"21","key":"e_1_3_2_67_1","first-page":"2095","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin CT","year":"2017","unstructured":"Ritchlin CT , ColbertRA , GladmanDD. Psoriatic arthritis. N. Engl. J. Med.376(21), 2095\u20132096 (2017).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2019.01.014"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2015.07.003"},{"issue":"10","key":"e_1_3_2_71_1","article-title":"Efficacy and safety results from a Phase II trial of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis","volume":"69","author":"Mease Pj KH","year":"2017","unstructured":"Mease Pj KH , MoritaA , KivitzAJet al. Efficacy and safety results from a Phase II trial of risankizumab, a selective IL-23p19 inhibitor, in patients with active psoriatic arthritis. Arthritis Rheumatol.69(Suppl. 10), (2017).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_2_72_1","volume-title":"Academy of American Dermatology Annual Meeting","author":"Papp K GM","unstructured":"Papp K GM , MoritaA , KivitizAet al. Safety and efficacy results from the open label extension of a Phase II trial of risankizumab, a selective IL-23p19 inhibitor in patients with active psoriatic arthritis. Presented at: Academy of American Dermatology Annual Meeting. Washington DC, USA, 1\u20135 March 2019."},{"key":"e_1_3_2_73_1","unstructured":"A study comparing risankizumab to placebo in subjects with active psoriatic arthritis including those who have a history of inadequate response or intolerance to biologic therapy(ies).Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT03671148"},{"key":"e_1_3_2_74_1","unstructured":"A study comparing risankizumab to placebo in subjects with active psoriatic arthritis (PsA) who have a history of inadequate response to or intolerance to at least one disease modifying anti-rheumatic drug (DMARD) Therapy.Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT03675308"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30570-6"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30233-4"},{"key":"e_1_3_2_77_1","unstructured":"A study to assess the efficacy and safety of risankizumab in subjects with ulcerative colitis who responded to induction treatment in M16-067 or M16-065. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT03398135"},{"key":"e_1_3_2_78_1","unstructured":"A study of the efficacy and safety of risankizumab in subjects with moderately to severely active Crohn\u2019s disease. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT03105128"},{"key":"e_1_3_2_79_1","unstructured":"A study to assess the efficacy and safety of risankizumab in subjects with moderately to severely active Crohn\u2019s disease who failed prior biologic treatment. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT03104413"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1233"},{"key":"e_1_3_2_81_1","volume-title":"American Academy of Dermatology Annual Meeting","author":"Strober B BA","unstructured":"Strober B BA , MenterA , SinvhalRet al. Risankizumab treatment is associated with low and consistent infection rates over time in patients with moderate to severe psoriasis: analysis of pooled clinical trial data. Presented at: American Academy of Dermatology Annual Meeting. Washington DC, USA, 1\u20135 March 2019."},{"key":"e_1_3_2_82_1","volume-title":"American Academy of Dermatology Annual Meeting","author":"Leoanrdi CBH","unstructured":"Leoanrdi CBH , WuJ , SinvhalRet al. Long-term safety of risankizumab in patients with moderate to severe psoriasis: analysis of pooled clinical trial data. Presented at: American Academy of Dermatology Annual Meeting. Washington DC, USA, 1\u20135 March 2019."},{"key":"e_1_3_2_83_1","volume-title":"American Academy of Dermatology Annual Meeting","author":"Reich KGK","unstructured":"Reich KGK , Tyrings , Sinvhalret al. Malignancy rates in patients with moderate to severe psoriasis during treatment with risankizumab: analysis of pooled clinical trial data. Presented at: American Academy of Dermatology Annual Meeting. Washington DC, USA, 1\u20135 March 2019."},{"issue":"7","key":"e_1_3_2_84_1","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp K","year":"2015","unstructured":"Papp K , GottliebAB , NaldiLet al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J. Drugs Dermatol.14(7), 706\u2013714 (2015).","journal-title":"J. Drugs Dermatol."},{"key":"e_1_3_2_85_1","unstructured":"SKYRIZI (risankizumab [package insert]). AbbVie Inc IL USA (2019)."},{"key":"e_1_3_2_86_1","unstructured":"A study to investigate safety with risankizumab in psoriatic arthritis subjects who have completed week 24 visit of study M16-002 (NCT02719171). Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT02986373"},{"key":"e_1_3_2_87_1","unstructured":"BI 655066\/ABBV-066\/risankizumab compared to placebo in patients with active psoriatic arthritis. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT02719171"},{"key":"e_1_3_2_88_1","unstructured":"A long term extension trial of BI 655066\/ABBV-066 (risankizumab) in patients with moderately to severely active Crohn\u2019s disease. Abbvie.https:\/\/ClinicalTrials.gov\/show\/NCT02513459"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt-2019-0116","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:09:28Z","timestamp":1715990968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt-2019-0116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,3]]},"references-count":86,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["10.2217\/imt-2019-0116"],"URL":"https:\/\/doi.org\/10.2217\/imt-2019-0116","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-07-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-08-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}